EP 2022505 B1 20111214 - GLP-1, exendin-4, peptide analogs and uses thereof
Title (en)
GLP-1, exendin-4, peptide analogs and uses thereof
Title (de)
GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
Title (fr)
GLP-1, exendine-4, analogues de peptides et utilisations associées
Publication
Application
Priority
- EP 02748271 A 20020730
- US 30907601 P 20010731
Abstract (en)
[origin: EP2275117A1] The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
IPC 8 full level
A61K 38/10 (2006.01); A61K 38/28 (2006.01); A61K 38/16 (2006.01); A61K 38/26 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 19/08 (2006.01); A61P 25/00 (2006.01); A61P 25/02 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 43/00 (2006.01); C07K 7/00 (2006.01); C07K 14/00 (2006.01); C07K 14/47 (2006.01); C07K 14/575 (2006.01); C07K 14/605 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP US)
A61P 3/10 (2018.01 - EP); A61P 5/50 (2018.01 - EP); A61P 7/12 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 19/08 (2018.01 - EP); A61P 21/02 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/02 (2018.01 - EP); A61P 25/14 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 39/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 14/575 (2013.01 - US); C07K 14/57563 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); A61K 38/2278 (2013.01 - US); A61K 38/26 (2013.01 - US)
Citation (examination)
MONTROSE-RAFIZADEH C ET AL: "High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 22 AUG 1997, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 21201 - 21206, ISSN: 0021-9258
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
DOCDB simple family (publication)
WO 03011892 A2 20030213; WO 03011892 A3 20040226; AT E408414 T1 20081015; AT E536881 T1 20111215; AU 2002317599 B2 20080403; AU 2008202893 A1 20080724; AU 2008202893 B2 20120112; CA 2455963 A1 20030213; CA 2455963 C 20170704; DE 60228972 D1 20081030; EP 1411968 A2 20040428; EP 1411968 A4 20050615; EP 1411968 B1 20080917; EP 2022505 A2 20090211; EP 2022505 A3 20090527; EP 2022505 B1 20111214; EP 2275117 A1 20110119; EP 2275117 B1 20161026; JP 2005501058 A 20050113; JP 2010090129 A 20100422; JP 2013139447 A 20130718; JP 5631578 B2 20141126; JP 5695097 B2 20150401; US 10941187 B2 20210309; US 2004242853 A1 20041202; US 2009253625 A1 20091008; US 2012329715 A1 20121227; US 2015072930 A1 20150312; US 7576050 B2 20090818; US 8278272 B2 20121002; US 8853160 B2 20141007
DOCDB simple family (application)
US 0224141 W 20020730; AT 02748271 T 20020730; AT 08162544 T 20020730; AU 2002317599 A 20020730; AU 2008202893 A 20080701; CA 2455963 A 20020730; DE 60228972 T 20020730; EP 02748271 A 20020730; EP 08162544 A 20020730; EP 10177860 A 20020730; JP 2003517083 A 20020730; JP 2009262568 A 20091118; JP 2013007734 A 20130118; US 201213594313 A 20120824; US 201414470528 A 20140827; US 31704208 A 20081218; US 48514004 A 20040401